X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
(AIDL)Here are the latest quarterly results of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA financial fact sheet and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
| No. of Mths Qtr. Ending |
3
Jun-15 |
3
Sep-15 |
3
Dec-15 |
3
Mar-16 |
3
Jun-16 |
3
Sep-16 |
3
Dec-16 |
3
Mar-17* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,320 | 1,284 | 1,446 | 1,588 | 1,395 | 1,382 | 1,503 | 1,116 | |
| Other income | Rs m | 17 | 15 | 15 | 21 | 16 | 18 | 98 | 64 | |
| Turnover | Rs m | 1,337 | 1,298 | 1,461 | 1,609 | 1,411 | 1,400 | 1,601 | 1,180 | |
| Expenses | Rs m | 1,267 | 1,321 | 1,329 | 1,556 | 1,236 | 1,349 | 1,353 | 1,163 | |
| Gross profit | Rs m | 53 | -37 | 116 | 32 | 160 | 32 | 149 | -47 | |
| Depreciation | Rs m | 43 | 45 | 44 | 42 | 41 | 41 | 40 | 37 | |
| Interest | Rs m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | Rs m | 27 | -67 | 87 | 11 | 135 | 10 | 208 | -20 | |
| Tax | Rs m | 0 | 0 | 0 | 5 | 29 | 2 | 48 | 9 | |
| Profit after tax | Rs m | 27 | -67 | 87 | 6 | 106 | 8 | 160 | -29 | |
| Gross profit margin | % | 4.0 | -2.9 | 8.1 | 2.0 | 11.4 | 2.3 | 9.9 | -4.3 | |
| Effective tax rate | % | 0.0 | 0.0 | 0.0 | 47.6 | 21.5 | 19.4 | 23.1 | -44.4 | |
| Net profit margin | % | 2.1 | -5.2 | 6.0 | 0.4 | 7.6 | 0.6 | 10.6 | -2.6 | |
| Diluted EPS | Rs | 1.1 | -2.7 | 3.5 | 0.2 | 4.2 | 0.3 | 6.4 | -1.2 | |
| Diluted EPS (TTM) | Rs | -0.2 | 8.3 | 17.1 | 2.1 | 5.2 | 8.2 | 11.2 | 9.8 | |
 Subscriber Feature |
||||||||||
More Pharmaceuticals Company Quarterly Results: AMAR REMEDIES ALEMBIC LTD SUN PHARMA DIVIS LABORATORIES AJANTA PHARMA
Compare ASTRAZENECA PHARMA With: AMAR REMEDIES ALEMBIC LTD SUN PHARMA DIVIS LABORATORIES AJANTA PHARMA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
After opening the day marginally higher, the share markets in India are currently trading below the dotted line. Sectoral indices are trading mixed with stocks in the information technology sector.
Net Profit lower due to exceptional items in the previous year.
US markets decline while other geographies grow in the quarter.
Currency fluctuation and one time provision impacts operating margins.
Base price erosion in the US and lower Zetia sales impacts profits.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
More Views on NewsWhile sales have fallen dramatically, net net home prices continue to hold on.
The secret of spotting multibaggers before they become a hit.
The most hated sector is offering the best trading opportunity. Are you ready?
The Income Tax return filing deadline is drawing near; if you have not already filed your taxes, here's how to do it.
Buffett's periodic underperformance to index fund.
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
